Skip to main content
. Author manuscript; available in PMC: 2020 Sep 21.
Published in final edited form as: J Am Coll Clin Pharm. 2020 May 2;3(6):1028–1037. doi: 10.1002/jac5.1250

FIGURE 4.

FIGURE 4

Comparison of the total number of each individual MRP, identified before (blue) and after (green) the PGx test results plus CDS reports became available. Asterisk (*) represents a significant difference (two-tailed Wilcoxon signed rank test). CDS, clinical decision support; MRP, medication-related problem; PGx, pharmacogenetic

HHS Vulnerability Disclosure